While none of these efforts have yet resulted in compounds investigated in the clinic due to lack of brain penetration [25], a non‐blood–brain barrier‐penetrating KMO inhibitor was shown to significantly improve Alzheimer’s disease symptoms and slow the disease progression [24]. Here, KMO is linked to early-onset autosomal dominant Alzheimer disease.